Immunotherapy is used in stage II/III melanoma for patients without the BRAF mutation as the adjuvant treatment in addition to surgery, and it uses monoclonal antibodies directed against immune checkpoints, which comprise membrane receptors that inhibit the anti-tumor activity of T cells. Here, BRAF is linked to neoplasm.